Expediting Clinical Trial Processes to Advance Brain Cancer Research

Commentary
Video

Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.

CancerNetwork® spoke with Yoshie Umemura, MD, about ongoing research efforts that her institution is organizing in the brain cancer field.

Umemura, the chief medical officer of the Ivy Brain Tumor Center, division chief of Neuro-Oncology, and the William and Joan Shapiro chair of Neuro-Oncology at Barrow Neurological Institute, highlighted a focus on the phase 3 Gliofocus trial (NCT06388733), in which she and co-investigators will evaluate treatment with niraparib (Zejula) for patients with newly diagnosed MGMT unmethylated glioblastoma. Additionally, she described how those at her institution have made use of a specific multidisciplinary collaboration at the Ivy Brain Tumor Center to advance their clinical trial efforts through each phase more quickly compared with traditional methods.

Transcript:

What we’re currently excited about is a phase 3 clinical trial that we are sponsoring. I’m the principal investigator at our site at the Ivy Brain Tumor Center, but as our institution, we’re sponsoring this international trial. [Although] we’re excited about the study itself, I think what’s most exciting is the way it happened. Phase 3 clinical trials often take years and years, sometimes over a decade, to [progress] from phase zero, phase 1, and phase 2 to phase 3. It takes forever. Even just opening one phase 2/3 study, from talking about the concept to getting it across to the starting line, can take years and years.

Because we have a unique platform where we try to take away some red tape safely [with] some of the multidisciplinary, creative minds that we have here, the platform was set [for us to] push from the early phase to the late phase quickly. We were able to move it just in a few years from phase zero and phase 2 to a phase 3 international trial. Having that platform and proving that we can make that happen is extremely exciting because it’s not going to be just one drug or one trial that’s going to make a difference. When there is one positive or negative trial, there are a lot of follow-up questions and follow-up trials. We can’t take 15 to 30 years to answer one simple question; we need to be able to do a lot of trials safely and effectively and have that platform to show that we can do this much quicker than the traditional method. It’s exciting.

Recent Videos
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.